Based on public company data, revenues for biotech companies in established biotech centers (defined as the US, Europe, Canada and Australia) grew 10.1% last year to $98.8 billion. However, nearly all of this growth was due to 17 US “commercial leaders” (defined as firms with over $500 million in sales). Total biotech R&D spending rose 14.6% to $29.1 billion. Revenues for US companies increased 12.9% to $71.9 billion, and R&D spending grew 20.1% to $23.3 billion. But the number of US public and private biotech firms declined 1.2% to 2,349. For US publicly traded companies, the biotech drug pipeline grew 9% to 5,634 products. In 2013, revenues for European biotech companies rose 2.8% to $21.0 billion, with R&D expenses down 3.7% to $4.8 billion. The number of European public and private biotech firms declined 1.0% to 2,083. However, the number of biotech product candidates at European companies rose 10% to 2,743, led by UK companies, which have 464 products in development.

Source: Ernst & Young